Archives of Physical Medicine and Rehabilitation
Volume 89, Issue 5 , Pages 799-806 , May 2008

Repeated Treatments With Botulinum Toxin Type A Produce Sustained Decreases in the Limitations Associated With Focal Upper-Limb Poststroke Spasticity for Caregivers and Patients

Presented in part to the American Academy of Physical Medicine and Rehabilitation, October 27–30, 2005, Philadelphia, PA; and the International Conference on the Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, June 23–25, 2005, Denver, CO.

  • Elie P. Elovic, MD

      Affiliations

    • Kessler Medical Rehabilitation Research and Education Center, West Orange, NJ
    • Department of Physical Medicine and Rehabilitation UMDNJ-NJ Medical School, Newark, NJ
    • Corresponding Author InformationReprint requests to Elie P. Elovic, MD, 1199 Pleasant Valley Way, West Orange, NJ, 07052
    • ,
  • Allison Brashear, MD

      Affiliations

    • Department of Neurology, Wake Forest University, Winston-Salem, NC
    • ,
  • Darryl Kaelin, MD

      Affiliations

    • Acquired Brain Injury Program, Shepherd Center, Atlanta, GA
    • ,
  • Jingyu Liu, PhD

      Affiliations

    • Allergan Inc, Irvine, CA.
    • ,
  • Scott R. Millis, PhD

      Affiliations

    • School of Medicine, Wayne State University, Detroit, MI
    • ,
  • Richard Barron, MS

      Affiliations

    • Allergan Inc, Irvine, CA.
    • ,
  • Catherine Turkel, PharmD, MBA

      Affiliations

    • Allergan Inc, Irvine, CA.

References 

  1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  2. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515–522
  3. Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35:134–139
  4. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl. 1997;6:S1–S13
  5. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl. 1997;6:S21–S35
  6. Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr. 2005;63:30–33
  7. Mayo NE, Wood-Dauphinee S, Cote R, Durcan L, Carlton J. Activity, participation, and quality of life 6 months poststroke. Arch Phys Med Rehabil. 2002;83:1035–1042
  8. Sturm JW, Donnan GA, Dewey HM, et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2004;35:2340–2345
  9. Elmstahl S, Malmberg B, Annerstedt L. Caregiver's burden of patients 3 years after stroke assessed by a novel caregiver burden scale. Arch Phys Med Rehabil. 1996;77:177–182
  10. Anderson CJ, Linto J, Stewart-Wynne EG. A population-based assessment of the impact and burden of caregiving for long-term stroke survivors. Stroke. 1995;26:843–849
  11. Draper BM, Poulos CJ, Cole AM, Poulos RG, Ehrlich F. A comparison of caregivers for elderly stroke and dementia victims. J Am Geriatr Soc. 1992;40:466–467
  12. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004;63:1971–1973
  13. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000;69:217–221
  14. Kozma CM, Burch SP, Childers MK, Barron R. Effect of botulinum toxin type A on health-related quality of life in stroke patients with spasticity. [abstract] Ann Neurol. 2001;50(Suppl 3):78
  15. Lagalla G, Danni M, Reiter F, Ceravolo MG, Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil. 2000;79:377–384
  16. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400
  17. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intra-rater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002;83:1349–1354
  18. Bakheit AM, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry. 2004;75:1558–1561
  19. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;10:2402–2406
  20. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8:559–565
  21. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306–1310
  22. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000;14:5–13
  23. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540–542
  24. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA. 1993;270:2475–2477
  25. van Straten A, de Haan RJ, Limburg M, Schuling J, Bossuyt PM, van den Bos GA. A stroke-adapted 30-item version of the Sickness Impact Profile to assess quality of life (SA-SIP30). Stroke. 1997;28:2155–2161
  26. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72
  27. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108
  28. The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208
  29. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In:  Jankovic J,  Hallett M editor. Therapy with botulinum toxin. New York: Marcel Dekker; 1994;p. 93–107
  30. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika. 1988;75:383–386
  31. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–117
  32. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999;66:612–616
  33. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16:770–778
  34. Marra CA, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care. 2004;42:1125–1131
  35. Nowels D, McGloin J, Westfall JM, Holcomb S. Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. Qual Life Res. 2005;14:95–105
  36. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) (I: Conceptual framework and item selection). Med Care. 1992;30:473–483
  37. Gianino JM, York MM, Paice JA, Shott S. Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs. 1998;30:47–54
  38. Middel B, Kuipers-Upmeijer H, Bouma J, et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry. 1997;63:204–209
  39. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology. 1996;46:26–29
  40. Botulinum toxin. Consens Statement. 1990;8(8):1–20
  41. Yablon S, Daggett S, Brin M. Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment in neuromuscular disorders. [abstract] Neurology. 2005;64(Suppl 1):A72
  42. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29:549–556

 Supported by Allergan Inc.

 A commercial party having a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit upon the author or one or more of the authors. Elovic has received grant funding from Allergan and Merz, is on the speakers bureau of Allergan, and is on the advisory boards of Allergan, Merz, and Solstice. Brashear has received grant funding from Allergan, Merz, Solstice, and Ipsen and has a consulting agreement with Allergan and Merz. Kaelin has received grant funding from Allergan and is on the speakers bureau of Allergan. Liu was an employee of Allergan and had stock in Allergan at the time the study was conducted. Barron was an employee of Allergan and had stock options in Allergan at the time the study was conducted. Turkel is an employee of Allergan and has both stock and stock options in Allergan. Merz and Ipsen manufacture botulinum toxin type A; Solstice manufactures botulinum toxin type B.

PII: S0003-9993(08)00082-8

doi: 10.1016/j.apmr.2008.01.007

Archives of Physical Medicine and Rehabilitation
Volume 89, Issue 5 , Pages 799-806 , May 2008

Article Tools

* Image Usage & Resolution